Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

Not Applicable

Completed

• Conditions: Diabetic Gastroparesis; Gastroesophageal Reflux Disease
• Interventions: Other: intervention letter

• Registration Number: NCT01126034
• Lead Sponsor: University of Pennsylvania

Brief Summary

The investigators hypothesized that:

1) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2007-03
• Primary Completion: 2008-04
• Study Completion: 2008-04
• Study First Submitted: 2010-05-17
• Study First Submitted QC: 2010-05-18
• Study First Posted: 2010-05-19
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-03
• Last Update Posted: 2015-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

• Physicians at University of Pennsylvania Health System who ordered an active metoclopramide prescription with a questionable indication.

Read More

Exclusion Criteria

• Physicians-in-training (e.g., residents, fellows)
• Physicians how were investigators on this study
• Physicians serving on the the University of Pennsylvania Drug Use and Effects Committee or Information Technology Oversight Board

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
intervention	intervention letter	Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components: 1. The name and medical record # of the patients involved 2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy 3. A reminder of the adverse effect of long-term metoclopramide therapy 4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients 5. A request that the physician document the discontinuation trial in the electronic medical record

Primary Outcome Measures

Name	Time	Method
Discontinuation of metoclopramide therapy	12 weeks after intervention period	Twelve weeks after the intervention period, we searched the medical records of patients in the intervention and non-intervention groups to determine whether discontinuation of metoclopramide therapy had taken place.

Trial Locations

Locations (1)

University of Pennsylvania Center for Clinical Epidemiology and Biostatistics; 🇺🇸 Philadelphia, Pennsylvania, United States